-
Co-stimulation effect and research progress of humanized monoclonal antibody CD28
Time of Update: 2022-09-14
The co-stimulation process in which CD28 is involved can produce a number of important molecular effects:Induces the expression of IL-2R (interleukin-2 receptor) on the surface of T cells, thus allowing cells to receive a third signal;2.
-
Express delivery of self-amplified mRNA COVID-19 vaccine stimulates a wide range of antibody and T
Time of Update: 2022-01-08
Image source: The key results of the first cohort (n=10, 10 µg dose level) of Gritstone bio's official website trial are as follows: The new CD8-positive T cell response covers a wide range of non-spike protein epitopes, including Many T cell targets that have been validated in convalescent patients prove the vaccine's potential to prevent the new crown variants .
-
Courier's stimulating antibody level is 3.5 to 7.5 times that of the approved vaccine
Time of Update: 2021-10-21
▎Editor of WuXi AppTec's content team On October 13, 2021, VBI Vaccines announced that it is investigating the third-generation 3 hepatitis B virus (HBV) candidate vaccine Sci-B-Vac, which is being tested in 18-45-year-old adults.
-
Clin Cancer Res: The efficacy of anti-colony stimulating factor monoclonal antibody Lacnotuzumab
Time of Update: 2021-10-20
Lacnotuzumab (Lacnotuzumab, an anti-colony stimulating factor monoclonal antibody)Female patients with advanced TNBC who have high levels of tumor-associated macrophages and are not suitable for surgery or radiotherapy were recruited and randomly divided into two groups to receive gemcitabine-carboplatin + latuzumab (10 mg/kg·3 weeks) or gemcitabine-carbohydrate Platinum treatment .
-
Immune stimulant coupled with monoclonal antibody Cinda Biosciences collaborates to develop innovative anti-cancer therapies
Time of Update: 2021-10-11
The two parties will combine Cinda's proprietary antibody drug portfolio and R&D capabilities for undisclosed tumor targets, and Bolt's advanced ISAC technology and expertise in the field of myeloid cells to jointly develop three new anti-cancer immunotherapy drugs, which are expected to provide patients Bring significant benefits .
-
Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology
Time of Update: 2021-09-13
(NASDAQ: BOLT) (hereinafter referred to as "Bolt"), a biotechnology company in the clinical stage, has created an effective binding antibody Targeting precision and new immunotherapies for the innate and adaptive immune systems have jointly announced today that the two parties have reached a new drug research and development agreement to jointly develop three antibody-immunostimulatory conjugate (ISAC) candidate drugs for the treatment of tumors .
-
Express | Key Phase 3 clinical results of the new hepatitis B vaccine published, stimulating antibody levels 5-8 times the approved vaccine
Time of Update: 2021-05-21
▎Editor of WuXi AppTec's content team On May 12, 2021, VBI Vaccines (hereinafter referred to as VBI) announced that the key phase 3 clinical trial data of its preventive 3-antigen hepatitis B virus (HBV) vaccine candidate in adults is in The Lancet Infectious Published on Diseases.
-
NEJM: A one-time inoculation stimulates a long-lasting negation antibody response, and Johnson
Time of Update: 2021-01-27
Ad26.COV2.S was effective in stimulating the immune response of the antibody in both adults and the elderly (Photo source: Source: Reference) Participants in the group over 65 years of age achieved 96% (low dose) and 88% (high dose) of mesoantr antibody serum conversion rates, respectively, 29 days after the first vaccination.
-
The new AIDS vaccine stimulates a strong antibody response in animal experiments
Time of Update: 2020-12-20
Then Jiang Zhu and colleagues further optimized the vaccine strategy, connecting stable Env trimers (up to 60 at a time) to a single nanoparticle that simulates the sphere structure of the entire virus.
-
vaccination stimulates antibodies and cellular immune responses.
Time of Update: 2020-10-20
in this regard, the researchers will use very low doses of the candidate virus vaccine in Phase 2a clinical trials to simulate new coronavirus infections and test the immune memory response of vaccinated participants.
-
Nat commun: artificial protein can stimulate the production of anti HIV antibody
Time of Update: 2019-02-28
February 28, 2019 / BIOON / - there are a lot of carbohydrates on the surface of HIV-1 to camouflage the protein env on the surface of HIV-1, so that HIV-1 can avoid the humoral immunity of human body